Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties [1][2] - The company has stated that its control has not changed, and the board of directors is operating normally, with financial and operational management remaining stable [2] - Xu Xiren remains the actual controller of the company, having authorized other executives to perform his duties during his absence [2] Company Background - Xu Xiren has been in control of Beijing University Pharmaceutical for only three months, having acquired control through a transaction involving the purchase of 100% of Southwest Synthetic Pharmaceutical Group [3] - The company has a long history, originally established in 1965, and has undergone several ownership changes, including being part of the Ping An Group and later transitioning to Xu Xiren's control in late 2024 [4] - The company reported a revenue of 957 million yuan for the first half of 2025, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [4] Market Performance - As of October 29, the stock price of Beijing University Pharmaceutical closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Points - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained and is temporarily unable to perform his duties [1] - The company has stated that its control has not changed and that its board of directors is operating normally [2] - Xu Xiren remains the actual controller of the company despite his detention [2] Company Control and Management - The company has made arrangements for its operations, with Xu Xiren authorizing other executives to perform his duties during his absence [2] - Xu Xiren acquired control of Beijing University Pharmaceutical through a transaction in December 2024, purchasing the controlling stake for 1 yuan while assuming significant debts [3] - Xu Xiren has held the positions of actual controller, chairman, and president of the company since his appointment in July 2025 [4] Financial Performance - In the first half of 2025, the company reported revenues of 957 million yuan, a year-on-year decrease of 5.04%, while net profit attributable to shareholders reached 100 million yuan, an increase of 15.51% [4] - The termination of a long-term service contract with Peking University International Hospital in April 2025 is expected to reduce the company's sales revenue and net profit in the second half of 2025 [4] Market Reaction - As of October 29, the company's stock price closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [5]

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical (北大医药), Xu Xiren, has been criminally detained, affecting his ability to perform his duties, while the company's control and operations remain stable [2][6]. Group 1: Management Changes - Xu Xiren has temporarily delegated his responsibilities to board member Chen Yuezhong and executive vice president Yu Mengchuan due to personal reasons [5]. - The delegation of authority is effective from the date of the written authorization and will remain in effect until Xu Xiren provides written notice to terminate it [5]. Group 2: Company Operations - As of the announcement date, the company has stated that its control has not changed, the board is functioning normally, and its financial and operational management is stable [2][6]. - The company is currently unaware of the progress or conclusions of the investigation into Xu Xiren's detention [6]. Group 3: Financial Impact - Following Xu Xiren's leadership, the company has faced challenges, including the termination of a long-term service contract with Beijing University International Hospital, which is expected to reduce sales revenue by approximately 600 million yuan and net profit by about 40 million yuan in 2025 [7]. - The company anticipates a revenue decrease of approximately 1.027 billion yuan starting in 2026, which is about 49.85% of the 2024 revenue [7].

Core Viewpoint - The chairman and president of Peking University Medicine, Xu Xiren, has been criminally detained and is temporarily unable to perform his duties, but the company's control remains unchanged and operations are normal [2][4]. Group 1: Company Leadership Changes - Xu Xiren has been detained and is cooperating with investigations, leading to a temporary delegation of his responsibilities to other executives [2][4]. - The company has arranged for the board to operate normally, and financial and operational management remains stable [4]. - Xu Xiren remains the actual controller of Peking University Medicine despite his detention [4][6]. Group 2: Background of Xu Xiren - Xu Xiren, born in April 1979, has a master's degree and has held various positions, including at Standard Chartered Bank [6]. - He acquired control of Peking University Medicine through a transaction involving the purchase of 100% of Southwest Synthetic Pharmaceutical Group for a nominal price, assuming significant debt [7]. - He has held the positions of actual controller, chairman, and president of the company since his appointment in July 2025 [7][8]. Group 3: Company Financial Performance - In the first half of 2025, Peking University Medicine reported revenues of 957 million yuan, a year-on-year decrease of 5.04%, while net profit attributable to shareholders was 100 million yuan, an increase of 15.51% [8]. - The termination of a long-term service contract with Peking University International Hospital in April 2025 is expected to negatively impact sales revenue and net profit in the second half of 2025 [8]. Group 4: Market Performance - As of October 29, the stock price of Peking University Medicine closed at 6.17 yuan per share, with a total market capitalization of 3.677 billion yuan [9].

Core Points - The chairman and president of Beijing University Pharmaceutical Co., Ltd., Xu Xiren, has been criminally detained and is temporarily unable to perform his duties [1][4] - The company has made arrangements for the board's operation and management to continue normally [2][4] - The company has authorized board member Chen Yuezhong to act as chairman and executive vice president Yu Mengchuan to act as president and legal representative [2][4] Company Governance - The company has a robust governance structure and internal control mechanisms in place [1][4] - The company will operate in accordance with relevant laws and regulations, including the Company Law and Shenzhen Stock Exchange listing rules [4] Current Status - As of the announcement date, the company's control has not changed, and its board operations, financial, and operational management remain normal [2][4][5] - The company is monitoring the investigation's progress and will fulfill its information disclosure obligations [5]

Major Events - Shanghai Zhiyuan Hengyue Technology completed the tender offer for Shangwei New Materials, acquiring 58.6232% of the shares, with trading resuming on October 30, 2025 [4] - Peking University Pharmaceutical's chairman and president Xu Xiren has been detained for criminal investigation, but the company's control and operations remain normal [5] - China Unicom's chairman Chen Zhongyue resigned due to work adjustments, effective October 29, 2025 [6][7] - CITIC Financial Assets increased its stake in Hangyang Co., Ltd. to 5% through a block trade, reflecting confidence in the company's future [8] - Haoshi Electromechanical's subsidiary plans to invest 232 million yuan in a high-end equipment intelligent manufacturing project [9] - Zhejiang Xiantong's second shareholder Li Qifu plans to invest 130 million yuan in Qiteng Robotics to enhance production capacity [10] - Qianjiang Biochemical's subsidiary has completed a project for bio-pesticide production, with an annual capacity of 3,261 tons [11] - Dongni Electronics will face risk warnings and a one-day suspension due to an administrative penalty [12] - Jindao Technology signed a strategic cooperation agreement with Hangcha Group to develop robotic joint modules [14] Performance Overview - Kweichow Moutai reported Q3 net profit of 19.224 billion yuan, a 0.48% increase year-on-year, with total revenue of 39.064 billion yuan [15] - Huibai New Materials achieved a Q3 net profit of 27.1307 million yuan, a 3066.26% increase year-on-year, with revenue growth of 49.59% [16] - Zangzi Island reported a Q3 net loss of 42.5226 million yuan, with revenue down 19.92% [17] - OFILM reported a Q3 net profit of 40.8235 million yuan, a 411.91% increase year-on-year, with revenue growth of 21.15% [18] - China Rare Earth's Q3 net profit was 30.4752 million yuan, down 26.43% year-on-year, with revenue declining 22.4% [19] - Tianqi Lithium reported a Q3 net profit of 95.4855 million yuan, turning a profit after previous losses [20] - New Yisheng's Q3 net profit was 2.385 billion yuan, a 205.38% increase year-on-year, driven by AI-related sales growth [21] - Industrial Fulian's Q3 net profit increased by 49% year-on-year [22] - CICC's Q3 net profit grew by 130% year-on-year [23] - Tianpu Co., Ltd. reported a Q3 net profit increase of 33% [24] - BlueFocus reported a Q3 net profit of 99.2389 million yuan, a 265.47% increase year-on-year [25] - Ningshui Group's Q3 net profit was 21.7388 million yuan, a 347.57% increase year-on-year [26] - Shoukai Co. reported a Q3 net loss of 3.105 billion yuan [27] - Xiamen Xiangyu's Q3 net profit was 601 million yuan, a 443.17% increase year-on-year [29] - Huaneng Intelligent reported a Q3 net loss of 53.8408 million yuan, a significant decline [30] - Zhongjin Gold's Q3 net profit increased by 39.18% year-on-year [31] - Shandong Gold's Q3 net profit increased by 92% year-on-year [32] - Yahua Group's Q3 net profit was 198 million yuan, a 278.06% increase year-on-year [33] - Western Gold's Q3 net profit increased by 168% year-on-year [34] - Laobai Gan Liquor reported a 28% decline in net profit for the first three quarters [35] - Kaiying Network's Q3 net profit was 633 million yuan, a 34.51% increase year-on-year [36] - Tongchen Beijian reported a Q3 net profit of 171 million yuan, turning a profit from previous losses [37] - Nanshan Holdings' Q3 net profit increased by 203.51% year-on-year [38] - China Merchants Bank's Q3 net profit was 38.842 billion yuan, a 1.04% increase year-on-year [39] - Huahong Technology's Q3 net profit increased by 7111% year-on-year [40] - Fangda Special Steel's Q3 net profit increased by 1368.1% year-on-year [41] Shareholding Changes - WuXi AppTec's controlling shareholder plans to reduce its stake by up to 2% [43] - Hecai Technology's major shareholder Bosch China plans to reduce its stake by up to 3% [44] Major Contracts - China Electric Power Construction signed a contract worth 6.568 billion yuan for a hospital project in Peru [45] - Lanshi Heavy Industry signed a significant contract in the nuclear energy sector worth 581 million yuan [46] - Guoke Military Industry's subsidiary signed a major sales contract worth 466 million yuan [48]

Core Viewpoint - The chairman and president of Beijing University Pharmaceutical, Xu Xiren, has been criminally detained, affecting his ability to perform duties, while the company has appointed other executives to take over his responsibilities [1][4]. Group 1: Company Announcement - On October 25, the company announced that Xu Xiren temporarily could not perform his duties due to personal reasons and authorized Chen Yuezhong to act as chairman and Yu Mengchuan as president [4]. - The authorization is effective from the date of signing until Xu Xiren provides written notice to terminate it [4]. - The company has assured that its governance structure and internal control mechanisms are intact, and operations remain normal despite the leadership change [4]. Group 2: Company Background - Beijing University Pharmaceutical was established in 1965 and listed on the Shenzhen Stock Exchange in 1997 [5]. - The company became a member of the Ping An Group in 2022 and is controlled by Xu Xiren [5]. - The company focuses on drug research, production, and sales, with a portfolio of 166 drug approvals and 13 first-generic drug approvals [5]. Group 3: Financial Performance - In the first half of the year, the company reported total revenue of 957 million yuan, a decrease of 5.04% year-on-year, while net profit increased by 15.51% to 100 million yuan [6].

突发。 北大医药（000788）10月29日晚间公告，公司于近日得到有关部门通知，获悉公司董事长、总裁徐晰人被刑事 拘留，正在配合相关部门调查，暂时无法正常履职。 早在10月25日，北大医药就发布公告称，公司于近日收到公司董事长、总裁徐晰人的书面《授权委托书》，徐 晰人因个人原因暂时无法履职，故授权公司董事陈岳忠代为行使董事长职责，授权公司常务副总裁余孟川代为 行使总裁及法定代表人职责。授权期限自董事长、总裁徐晰人签署书面《授权委托书》之日起生效，有效期自 徐晰人以书面形式提前通知受托人及公司终止上述授权时止。 公告称，目前，公司已对相关工作进行了妥善安排。 公司拥有完善的治理结构及内部控制机制，将按照《公 司法》《深圳证券交易所股票上市规则》《上市公司治理准则》及《公司章程》等法律法规和相关制度规范运 作。截至本公告披露日，公司控制权未发生变化，公司董事会运作正常，公司财务及生产经营管理情况正常。 公告还称，截至本公告披露日，公司尚未知悉相关调查的进展及结论，公司将持续关注上述事项的后续情况， 并严格按照有关法律、法规的规定和要求，及时履行信息披露义务并提示相关风险。 版权声明 证券时报各平台所有原创内容， ...

Core Viewpoint - The announcement from Peking University Medicine Co., Ltd. indicates that the chairman and president, Xu Xiren, has been criminally detained and is currently cooperating with investigations, temporarily unable to perform his duties. The company asserts that its control, board operations, and financial management remain normal [3][4][5]. Group 1: Company Management Changes - On October 25, the company disclosed that Xu Xiren authorized board member Chen Yuezhong to act as chairman and executive vice president Yu Mengchuan to act as president and legal representative due to his inability to perform his duties [5][7]. - The company has established a robust governance structure and internal control mechanisms to ensure compliance with relevant laws and regulations during this transition [5]. Group 2: Company Background - Peking University Medicine has over 50 years of pharmaceutical manufacturing history and offers a wide range of products, including over 100 varieties across 10 major categories such as anti-tumor and cardiovascular drugs [12]. - The company was originally founded in 1965 and successfully listed on the Shenzhen Stock Exchange in 1997. It became a member of the New Fangzheng Group after a change in control in 2022 [12]. - Xu Xiren became the actual controller of the company in December 2024 after acquiring a 22.22% stake through a symbolic price transaction and debt assumption [12]. Group 3: Relationship with Peking University - As of August 2023, Peking University no longer has any direct relationship with the company, having undergone two rounds of actual controller changes since December 2022 [8]. - The company is in the process of gradually changing its name to reflect this separation from Peking University [8]. Group 4: Xu Xiren's Profile - Xu Xiren, born in April 1979, has a master's degree and has held various positions, including chairman and general manager of New Advantage Industry Group [8][9]. - He has connections to numerous enterprises across various sectors, including investment and public relations [9].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 10月29日，北大医药（000788.SZ）公告称，公司董事长、总裁徐晰人因配合相关部门调查被刑事拘 留，暂时无法正常履职。目前，公司已对相关工作进行了妥善安排，控制权未发生变化，董事会运作正 常，财务及生产经营管理情况正常。公司将持续关注上述事项的后续情况，并及时履行信息披露义务。 证券代码:000788 证券简称:北大医药 公告编号:2025-079 北大医药股份有限公司 关于公司董事长、总裁暂时无法正常履职的进展公告 特此公告。 北大医药股份有限公司(以下简称"公司")于2025年10月25日在巨潮资讯 网披露了《关于公司董事长、总裁授权公司董事代行董事长职责、授权公司常务 副总裁代行总裁及法定代表人职责的公告》(公告编号:2025-078)。公司董事 长、总裁徐晰人先生因暂时无法履职,授权公司董事陈岳忠先生代为行使董事长 职责,授权公司常务副总裁余孟川先生代为行使总裁及法定代表人职责。 公司于近日得到有关部门通知,获悉公司董事长、总裁徐晰人先生被刑事拘 留,正在配合相关部门调查,暂时无法正常履职。 目前, ...